All In Biotech

Drug Trial Radar · NCT04485481

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

A Double-Blind, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ADX-914 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Sep 8, 2020

Primary completion

Jan 12, 2022

Study completion Jan 12, 2022

Sponsor

Lead sponsor
Q32 Bio Inc.Industry
Sponsor type
Industry
First posted
Jul 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A two (2) part study to evaluate the safety, tolerability and PK of ADX-914

Conditions

  • Safety Issues

Interventions

  • ADX-914Drug

    Single dose from 0.1mg/kg to TBD

  • PlaceboDrug

    Matching single dose placebo

  • ADX-914Drug

    Multiple dose from TBD to TBD

  • PlaceboDrug

    Matching multiple dose placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse eventsTime frame: Screening to end of study, up to 18 weeks
  2. Number of subjects with Physical exam findingsTime frame: Screening to end of study, up to 18 weeks
  3. Number of subjects with Clinical safety lab changesTime frame: Screening to end of study, up to 18 weeks
  4. Number of subjects with Systolic blood pressure changesTime frame: Screening to end of study, up to 18 weeks
  5. Number of subjects with Heart rate changesTime frame: Screening to end of study, up to 18 weeks
  6. Number of subjects with 12 Lead ECG changesTime frame: Screening to end of study, up to 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.